
|Videos|June 2, 2014
Are Expensive New Hepatitis C Drugs Worth the High Cost?
Author(s)Davy James, Associate Editor
Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.
Advertisement
Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.
This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Current Pneumococcal Vaccination Recommendations: A Clinical Update
2
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
3
Semaglutide Reduces Time in Spent in Hospital, Admission Rates in Patients With Overweight or Obesity
4
From the Pharmacy Counter to the Kitchen Cabinet: Helping Patients Choose Quality Supplements
5

























